Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHA)

Add RCHA Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator mick, sunspotter, onthegreen
Search This Board:
Last Post: 7/1/2015 4:34:10 PM - Followers: 159 - Board type: Free - Posts Today: 0

RCHA Patent for Treatment of Hodgkin’s Lymphoma
Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma, utility patent application number 61998397, entitled COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF HODGKIN’S LYMPHOMA.
RCHA Recent News
Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug (IND) Application For The Treatment of Acute Myelocytic Leukemia
BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China.  This new batch of RP-323 represents a new second-generation compound with improved product usability and stability.  Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323.  Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.   
Rich Pharmaceuticals submitted its Investigational New Drug (IND) Application for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS in October 2014.  In connection with the IND, Rich Pharmaceuticals was required to manufacture sufficient quantities of RP-323 under GMP.
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin's Lymphoma and other blood related diseases.  Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life.  Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities.  Find out more at
WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:


Below is the indicated Product Pipeline for RCHA:

Here is a key piece from the news as to how it applies:
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."

Courtesy of Sibware: 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells (WBC) in patients depleted of these elements due to various conditions. 

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs, and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 


It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000. Based on this incidence,the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.

RCHA Key DD Posts:
Key RCHA & WX:NYSE Relationship
Respectfully, again, key with the Authorized Shares



Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003



Daily View

Weekly View

3 Month Daily View

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
RCHA News: Current Report Filing (8-k) 06/29/2015 04:29:11 PM
RCHA News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 06/29/2015 11:07:55 AM
RCHA News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 06/29/2015 09:56:25 AM
RCHA News: Securities Registration: Employee Benefit Plan (s-8) 06/18/2015 05:16:57 PM
RCHA News: Current Report Filing (8-k) 06/17/2015 05:08:23 PM
#7384  Sticky Note $RCHA recent news/filings mick 04/17/15 04:23:21 PM
#6618  Sticky Note "in the face of the massive gains we sunspotter 03/17/15 05:07:01 AM
#7861   mgmt plying ruff games wit shareholders by bigtime dilution/\ mick 07/01/15 04:34:10 PM
#7860   Will not matter with all the Conversions. Axeman 07/01/15 01:01:02 PM
#7859   15M Block, Allot of Giant buys hitting here PENNYMACHINE 07/01/15 11:52:54 AM
#7858   is it a dead duck mick ? sure valleyview 07/01/15 07:46:29 AM
#7857 mick 06/30/15 05:47:57 PM
#7855   35M Block hit .0002, Wow PENNYMACHINE 06/30/15 10:00:35 AM
#7854   In at $0.0002, hope the pump starts soon! :) Jclassy 06/30/15 12:55:31 AM
#7853   Personally, I don't think LG would be interested northandsouth1 06/29/15 03:03:04 PM
#7852   Doesn't look good Maybeismaybenot 06/29/15 02:10:14 PM
#7851   Filings out today PENNYMACHINE 06/29/15 11:12:33 AM
#7850   what do you mean when ?? it's already valleyview 06/29/15 07:26:29 AM
#7847   Very Interesting, Even says Verified by Transfer Agent, PENNYMACHINE 06/26/15 01:58:00 PM
#7841   No one will be alright once this thing Maybeismaybenot 06/26/15 11:58:54 AM
#7840   I'll be alright...its worth the risk but thanks brent818181 06/26/15 11:52:41 AM
#7839   you should GET OUT while you still can. Maybeismaybenot 06/26/15 11:47:39 AM
#7838   IM IN...lets go RCHA brent818181 06/26/15 10:44:14 AM
#7837   It may be possible for it to go stoprun 06/26/15 09:11:19 AM
#7836   It may be possible that no bid will valleyview 06/26/15 09:01:19 AM
#7835   yea give or take a few billion they Reedbetweendalines 06/26/15 08:50:52 AM
#7833   I think 35 billion but you might be Axeman 06/26/15 01:30:19 AM
#7832   is the A/S really 37.5 billion Reedbetweendalines 06/25/15 06:06:57 PM
#7831   What a cluster f ck Maybeismaybenot 06/25/15 03:31:29 PM
#7830   LOL. BEN WILL SELL EVERY LAST ONE! onthegreen 06/25/15 03:29:09 PM
#7829   Well..OS is heading over 3 billion soon and Axeman 06/25/15 02:16:38 PM
#7826   Why would someone hold these shares for months Maybeismaybenot 06/24/15 06:07:46 PM
#7824   Get real. anybody who buys based on Maybeismaybenot 06/24/15 01:33:30 PM
#7823   I made mention a few days ago of jonestint 06/24/15 01:16:12 PM
#7822   Are you worried about an R/S? Maybeismaybenot 06/24/15 01:14:15 PM
#7821   This is going higher, I'm accumulating in the Jclassy 06/24/15 12:57:23 PM
#7820   Without news I don't think the flip will Maybeismaybenot 06/24/15 10:50:59 AM
#7819   $RCHA Chart - PSAR Bull Flip - it ospreyeye 06/24/15 01:47:38 AM
#7818   Nope. Just waiting to see if Ben and Axeman 06/23/15 01:18:30 PM
#7817   Now would be a great time for the PUMP Maybeismaybenot 06/23/15 01:17:31 PM
#7816   Is that your 1.4 on the bid? Maybeismaybenot 06/23/15 01:08:45 PM
#7815   Well look at that. .0003 again. I might Axeman 06/23/15 01:02:54 PM
#7814   Its very hard to tell you for sure Chakumudzi 06/23/15 10:14:42 AM
#7813   Anyone know where I can buy a TOMBSTONE? tiller 06/23/15 07:59:57 AM
#7811   June 16 2015 OS is 2,478,815,990. Probably Axeman 06/23/15 02:10:50 AM
#7810   Tell ya what I think, this baby is northandsouth1 06/23/15 01:35:51 AM
#7809   What r your thoughts on this stock.. danlevitan 06/22/15 11:53:49 PM
#7808   This one could double soon danlevitan 06/22/15 06:30:21 PM
#7807   RCHA---- Total Authorized Capital: $ 100,000.00 New Stock Chakumudzi 06/22/15 03:43:31 PM
#7802   Where are you getting "with unlimited amount of C.G.B Spender 06/22/15 01:56:33 PM
#7801   with unlimited amount of shares with 35 billion AS. Axeman 06/22/15 01:16:30 PM
#7800   The volume builds... jonestint 06/22/15 12:49:12 PM
#7799   My little birdie PROOFREADS the 8Ks. All I'm jonestint 06/22/15 12:02:35 PM
#7798   OS is approaching 3 billion Axeman 06/22/15 11:01:00 AM
#7797   This Could go much higher mkyj 06/22/15 10:32:11 AM
#7796   (Rcha) I'm watching this one mkyj 06/22/15 10:31:22 AM
#7795   From the 10Q in February: mplscubfan 06/22/15 10:21:18 AM